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Abstract 
 Human pluripotent stem cells (hPSCs) can acquire non-random genomic 
variation during culture. Some of these changes are common in tumours and 
confer a selective growth advantage in culture. Additionally there is evidence 
that reprogramming of human induced pluripotent stem cells (hiPSCs) 
introduces mutations as well. This poses a challenge to both the safety of clinical 
applications, and the reliability of basic research using hPSCs carrying genomic 
variation. A number of methods are available for monitoring the genomic 
integrity of hPSCs and a balance between practicality and sensitivity must be 
considered to choose the appropriate methods for each use of hPSCs. Adjusting 
protocols by which hPSCs are derived and cultured is an evolving process that 
is important to minimise acquired genomic variation. Finally, assessing genetic 
variation for its potential impact is becoming increasingly important as 
techniques to detect genome wide variation improve.      
 
Introduction 
 Human pluripotent stem cells (hPSCs) can be derived from embryos or induced 
from somatic cells (Takahashi et al., 2007, Yu et al., 2007, Thomson et al., 1998). 
These cells have the ability to produce cell types from any of the three germ layers and 
can self renew. Excitement surrounding hPSCs is fuelled by potential uses in studying 
development, modelling disease and regenerative medicine.  
7DNLQJ 3DUNLQVRQ¶V GLVHDVH DV DQ H[DPSOH GLVHDVH PRGHOV KDYH EHHQ
developed by reprogramming patients¶ fibroblasts to human induced pluripotent stem 
cells (hiPSCs) IDFLOLWDWLQJDEHWWHUXQGHUVWDQGLQJRIWKH3DUNLQVRQ¶VGLVHDVHgenotype 
(Soldner et al., 2009). Furthermore, through developing protocols for the differentiation 
of hPSCs to dopaminergic neurons a greater understanding of neuronal development 
cues has gradually built up (Perrier et al., 2004). This knowledge then allows the 
3 
gradual translation into regenerative medicine treatments (Kriks et al., 2011). 
Similarly using tissue from long QT patients, hiPSC derived cardiac myocytes 
have been generated which show a characteristic reduction in the delayed rectifier 
potassium current (Itzhaki et al., 2011). Furthermore the long QT hiPSC derived cardiac 
myocyte model was used to screen for pharmacological agents providing an 
improvement to the phenotype (Itzhaki et al., 2011).   
These examples demonstrate the importance of hPSC research in a wide array 
of fields. However, in order to realise this potential, hPSCs must be maintained, often 
in large numbers, in culture. hPSCs show apparent immortal self-renewal in culture 
which distinguishes them from their in vivo embryonic counterparts which quickly 
become restricted in fate (Andrews, 2002). Since their first derivation, numerous 
studies have shown that hPSCs are subject to genomic change within culture. 
Furthermore, hiPSCs show additional signs of genetic instability associated with the 
reprogramming process.  
This review aims to first summarise the current knowledge on acquired genomic 
change in hPSCs. Following this are discussions on emerging approaches to monitor, 
minimise and assess genomic change that are important considerations in the field of 
hPSC research.   
 
Genetic change in human pluripotent stem cell culture 
Genetic change can occur spontaneously in any cell but, through a combination 
of natural senescence and apoptosis, most never become established within the 
overall population. Indeed, post mortem neural tissue shows low level mosaicism which 
may help to produce functional diversity (Rehen et al., 2005) and normal pluripotent 
stem cell populations are likewise chromosomally heterogeneous (Peterson et al., 
2011). However, some hPSC cultures show non-random genetic change that can come 
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to dominate the population (Draper et al., 2004). Commonly these involve gains of parts 
of chromosomes 1, 12, 17 and 20 and losses of regions of chromosomes 10, 18 and 
22 (Figure 1) (Amps et al., 2011). 
For example, in one study over 50% of 30 human embryonic stem cell (hESC) 
lines maintained over 18 months developed karyotype abnormalities, with 17q and 
chromosome 12 trisomy being the most frequent change (Baker et al., 2007). 
Furthermore, the same karyotype abnormalities have been reported independently in 
other lines (Cowan et al., 2004, Mitalipova et al., 2005). In all cases the abnormalities 
were observed only after continued culture.  
These changes are not exclusive to hESCs. Using a technique that infers 
karyotype abnormalities from gene expression data, it was shown that genes on 
chromosome 12 were consistently overexpressed in hiPSC lines as well (Mayshar et 
al., 2010). Together these data imply that the genetic aberrations observed are 
characteristic of pluripotent stem cell culture, rather than the source of the cells from 
either embryo or fibroblast.  
In a large scale screening of 125 hESC lines by single-nucleotide polymorphism 
(SNP) array analysis a sub-chromosomal copy number gain of part of the long arm of 
chromosome 20 (20q11.21) was identified in twenty-two cell lines (Amps et al., 2011). 
In all cases the duplications overlapped, sharing a minimal amplicon region of 0.55MB 
pairs, and the same copy number variant (CNV) has been identified independently in 
both hESCs and hiPSCs (Laurent et al., 2011).  
Three genes within the 20q11.21 minimal amplicon are commonly expressed 
in hESCs. One of which, BCL2L1, forms two alternative transcripts that encode both a 
pro-apoptotic protein and an anti-apoptotic protein. In embryonic stem cells it is almost 
exclusively the anti-apoptotic protein, BCL-XL, that is expressed (Avery et al., 2013). 
This finding gives support to the hypothesis that the non-random genetic 
change observed within hPSCs is driven by selection resulting in advantageous genetic 
variation becoming widespread over long term culture. Using the 20q11.21 CNV as an 
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example, we can assume this arises randomly and because of the unlimited 
proliferative potential of hPSCs the extra dose of BCL-XL conferred by this CNV could 
confer a selective advantage through its anti-apoptotic effects. Therefore, continuous 
passaging of a cell culture carrying this CNV will lead to its gradual accumulation within 
the cell population. 
Experimental evidence for this model has been provided through the 
comparison of hESC lines carrying the 20q11.21 CNV with control hESC lines (Avery 
et al., 2013). In this study, population doubling times of 35 hours and 138 hours were 
reported respectively. Flow cytometry showed no difference in the distribution of cells 
throughout the cell cycle within each population and time-lapse confocal microscopy 
confirmed a similar absolute cell division time. This indicates that the reduced 
population doubling time observed in 20q11.21 CNV carrying cells was due to a 
reduction in apoptosis rather than an increase in proliferation. The action of BCL-XL 
specifically in this process was confirmed by overexpressing only BCL-XL in a separate 
cell line which mirrored the results of the cells carrying the whole 20q11.21 CNV. 
Strikingly, this process by which cells can acquire a growth advantage  upon 
prolonged culture closely resembles aspects of tumorigenesis (Figure 2), which is 
likewise thought to originate from mutations in a single cell that allow it to escape from 
tight growth control leading to selective clonal expansion (Fialkow et al., 1977). It is 
therefore possible that culture adaptation is an in vitro mimicry of this micro-
evolutionary process. This raises concerns for the clinical application of hPSCs as it is 
plausible for such genetic change to confer malignant properties. For example 
isochromosome of 12p is used as a clinical marker of testicular germ cell tumours 
(TGCT) (Bosl et al., 1989). Furthermore, fluorescent in situ hybridisation (FISH) in 
human embryonal carcinoma cells, the malignant counterpart to hESCs, found that 6/9 
carried the 20q11.21 amplification (Avery et al., 2013), which may suggest it can 
similarly drive growth advantage in malignant cells.  
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Genetic change has been detected on every chromosome, although 
aberrations on chromosome 4 are exceptionally rare, during hPSC culture (Amps et 
al., 2011).  However, a so far unanswered question is why particular aberrations, such 
as those on chromosomes 12, 17 and 20, are so common? Recently it has been 
demonstrated that under replicative stress hESCs fail to activate key proteins, such as 
CHK1 and ATR, involved in the S-phase checkpoint despite normal levels of 
expression (Desmarais et al., 2012). Furthermore hESCs showed an upregulation in 
apoptotic markers and caspase 3 activation. This suggests that an intrinsic 
characteristic of hESCs is to eliminate cells acquiring DNA damage without an attempt 
at repair. This may be a desirable mechanism for protecting genome integrity as 
genetic change in ESCs in vivo would be passed on to the whole organism and could 
prove catastrophic. These findings have relevance to the discussion of acquired 
genomic variation. If hESCs normally protect genomic integrity through apoptosis 
rather than DNA repair then an acquired variation such as the 20q11.21 CNV would 
provide a particular selective advantage. The resistance to apoptosis conferred by the 
extra dose of BCL-XL in cells carrying this CNV is likely to help them thrive under these 
conditions. This could go some way to explaining why chromosome 20q variations 
develop so commonly in hPSC culture.  
Thus far similar evidence for driving genes on chromosomes 12 and 17 has 
been elusive. This is largely due to the scale of the changes. The 20q minimal amplicon 
is only 0.55MB, so presented a limited number of candidate genes to investigate. In 
contrast the changes in chromosomes 12 and 17 usually involve a duplication of either 
the whole chromosome or an arm so pinpointing the driving genes involved is more 
difficult. 
Nevertheless, candidate genes have been suggested. For example the gene 
BIRC5, located at 17q25.3, is known to have anti-apoptotic properties and is highly 
expressed in teratomas, the tumours formed by hESCs (Blum et al., 2009). Likewise 
NANOG, found at 12p13.31, contributes to maintaining pluripotency (Mitsui et al., 
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2003), so if overexpressed may make cells more likely to continue self-renewal. 
However, detailed analysis shows the closest minimal amplicon falls upstream of 
NANOG on its unexpressed pseudogene (Laurent et al., 2011). Furthermore, the same 
minimal amplicon was found to be just as prevalent in the reference samples (Amps et 
al., 2011) and so is unlikely to be causing a change in cell behaviour. 
However it is important not to dismiss the possibility that the phenotypic growth 
advantage conferred by these chromosomal aberrations is a result of a change in 
expression of multiple genes. This could explain why genetic change involving these 
chromosomes tends to involve whole or large duplications. 
 
Epigenetic change 
The epigenetic status of a cell is highly important in gene expression and 
therefore dictating its specific phenotype (Ferguson-Smith, 2011). Particularly relevant 
are the processes of genome imprinting whereby DNA methylation patterns produce 
monoallelic expression of particular genes in a parent of origin manner (Butler, 2009). 
Previous studies had observed epigenetic instability in cultured mouse ESC 
(Humpherys et al., 2001) and hypothesised a link between assisted reproductive 
technology and epigenetic disorders (Butler, 2009). This prompted investigations into 
whether removing hESCs from their in vivo environment and prolonged culture could 
perturb epigenetic imprinting.  
In an early study of six imprinted genes in four hESC lines the normally 
paternally imprinted gene, H19, gained biallelic expression on prolonged culture (Rugg-
Gunn et al., 2005). The H19 gene stands out from the other five genes investigated 
since it acquires methylation during embryonic development. However, upon closer 
inspection the re-expressed allele of H19 still showed methylation typical of an 
imprinted gene suggesting the re-expression must occur through an alternative 
mechanism (Rugg-Gunn et al., 2005). 
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In further studies of over 2000 loci by restriction landmark genome scanning all 
six hESC lines showed high levels of epigenetic instability which was reliably fixed 
within the cell population (Allegrucci et al., 2007). Another study found that IGF2 
became biallelically expressed in an hESC line grown by one laboratory, whereas 
cultures of the same line grown by a different laboratory did not exhibit the same 
biallelic expression, which may suggest that culture conditions can have an effect on 
the epigenetic status of cultured hESCs (Rugg-Gunn et al., 2007). 
A more recent study of 205 hPSCs and 130 somatic samples provided 
interesting insight into tissue specific versus pluripotent epigenetic character (Nazor et 
al., 2012). This study also detailed the correlation between either hypermethylation or 
hypomethylation with the loss of allele specific expression of numerous genes in 
K36&¶V $GGLWLRQDOO\ WKH JURXS UHSRUWHG WKDW LQ IHPDOH K36&V ; FKURPRVRPH
inactivation was gradually lost with time in culture corresponding to a decrease in XIST 
expression and an increase in mRNA expression of genes on this chromosome. This 
type of epigenetic instability is particularly relevant when considering the use of hPSCs 
in the modelling of X-linked diseases as it could confound results (Mekhoubad et al., 
2012). 
 
Further considerations for induced pluripotent stem cells 
The issues discussed so far regarding genetic and epigenetic change in culture 
are similar for both embryonic and induced pluripotent stem cells (Seth et al., 2011). 
However, there are differences in hiPSCs that present further sources of genetic 
change in these cells.  
hiPSCs differ from hESCs in the fact that they are reprogrammed from somatic 
tissue. Originally, concerns were raised regarding the use of a retroviral vector for 
reprogramming (Takahashi et al., 2007) since the integration of the transgene can 
produce insertion mutations, and insertional mutagenesis has previously been seen to 
cause serious adverse effects in a gene therapy attempt (Hacein-Bey-Abina et al., 
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2003). Attempts to address this issue include the development of reprogramming 
methods using an episome vector. This is able to replicate extrachromosomally 
allowing reprogramming without integration. Furthermore, both vector and transgene 
can then be eliminated via drug selection (Yu et al., 2009). 
Mutations that may have been induced during reprogramming have indeed 
been reported to occur in early passages of iPSC (Hussein et al., 2011), perhaps due 
to increased replicative stress resulting from forced overexpression of reprogramming 
factors (Ruiz et al., 2015). However, a comparison of hiPSC lines derived by retroviral 
or episomal reprogramming showed no significant difference in the frequency of 
karyotype abnormalities (Taapken et al., 2011). Further, detailed DNA sequence 
comparisons of parental somatic cells and hiPSC derived from them have indicated 
that many, if not all of the mutations detected in the hiPSC pre-existed in the parental 
somatic cells (Gore et al., 2011, Ji et al., 2012, Rouhani et al., 2016) Due to the 
inefficiency of reprogramming, hiPSC lines usually have a clonal origin and therefore 
genetic change in just a single parental cell, not detectable in the bulk population 
because of limited sensitivity of the sequencing methods, could be carried through and 
PLVWDNHQO\LGHQWLILHGDVµQHZ¶JHQHWLFYDULDWLRQZKHQWKHKL36&FXOWXUHLVFRPSDUHGWR
the parent culture as a whole (Young et al., 2012).  Nevertheless, independent of 
µPXWDWLRQVRIRULJLQ¶ LH WKRVHWKHUHZHUHSUHVHQW LQ WKHSDUHQWDOFHOOVRUPD\KDYH
been induced during reprogramming, hiPSC do tend to acquire the same common 
variants seen in hESC during prolonged culture (Amps et al., 2011, Taapken et al., 
2011). 
 
 
Monitoring genetic change 
Monitoring hPSC cultures is important in the laboratory to ensure genetic 
change does not affect experimental results. It is also vital in clinical applications to 
ensure cells carrying potentially harmful genetic variation are not introduced into 
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patients. A number of techniques are available to detect genetic change with some 
screening the whole genome indiscriminately while others use probes targeted to 
known loci. The development of single cell based techniques makes it feasible to detect 
genetic change occurring in only a small minority of cells. All methods, however, have 
limitations and therefore judgement is required to ensure hPSCs are monitored to an 
extent that is adequate for their use in either the laboratory or clinical setting. 
 The traditional, though still highly relevant method for detecting genetic change 
in cell culture is by assessing the banding pattern of chromosomes in metaphase 
spreads. This was how some of the earliest genetic changes, such as those on 
chromosomes 12 and 17 were detected (Figure 1) (Draper et al., 2004). G-banding 
karyotype analysis has the advantage that it allows assessment of the whole genome 
for aberrations without any preconceived knowledge, but it is highly labour intensive 
and analysis usually requires outsourcing to skilled cytogeneticists. 
The process for G-banding involves preparing a certain number of metaphase spreads 
on a slide and scoring a random sample with the assumption that this is representative 
of the culture as a whole, although it is possible that differential growth patterns or 
detachment during harvesting of cells in mosaic cultures might distort this assumption. 
Recently, this assumption and the sensitivity of G-banding was tested systematically 
using mosaic cultures of hPSC containing known genetic changes at increasing 
percentages within the population (Baker et al., 2016). The results confirmed that 
acquired genetic change in hPSC is detected by G-banding at the same frequency as 
statistically predicted using random sampling. However, sensitivity is limited by cost 
and practicalities: typically a cytogeneticist might score 30 metaphases, but this will 
only reliably detect variants that are present in more than 18% of the cells in a mosaic 
culture (Table 1). A  lower limit of around 6% mosaicism requires scoring 100 
metaphase spreads, and to reliably detect variants present with less than 1% of the 
population requires screening over 500 metaphases, a number that is largely 
impracticable in routine cytogenetic practice. . 
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G-banding karyotype analysis, even using newly developed automated 
techniques, is mostly restricted to detecting large genetic aberrations over roughly 5Mb 
(Steinemann et al., 2013). Therefore, it is rare for small CNVs, such as the common 
20q11.21 CNV, to be detected in this way, and typically these require techniques such 
as SNP array or aCGH based analysis (Amps et al., 2011). The potential of this CNV 
to be harmful is still unknown. However, as described, its anti-apoptotic property is 
known to confer a growth advantage and so any plans clinical application involving 
hPSCs should take account of the inability of karyotype analysis to detect this CNV. 
Small CNVs such as that at 20q11.21 can be detected using probe based 
screening strategies, for example FISH. However, FISH suffers from many of the same 
issues as G-banding in that it is labour intensive.  Also, in practice, it has a limit of 
detection of around 5% due to false negatives, particularly in the case of tandem 
duplications when the signals from each copy may overlap and only one copy of the 
CNV is scored. 
To overcome sampling issues it may be possible to combine FISH with flow 
cytometry in order to conduct a high throughput screen. This interphase chromosome 
flow-FISH method has been tested on blood samples of myelodysplastic syndrome 
patients who often present with chromosome 7 monosomy (Keyvanfar et al., 2012). 
The study found the technique to reliably identify chromosome 7 monosomy without 
the need for laborious slide analysis. The automated flow cytometry process also 
allows the screening of thousands of cells at once making it less likely that a genetic 
aberration will go undetected due to small sample size. Furthermore the technique also 
provides a quantitative measure of the extent of aneuploidy in the sample.   
Recently a quantitative polymerase chain reaction (qPCR) based method has 
been developed which allows the detection of CNVs based on the comparison of PCR 
products using primers selected for target and reference regions (Baker et al., 2016). 
This technique was able to detect CNVs for chromosomes 12, 17 and 20 with a lower 
detection limit of 10%. This qPCR method provides a very useful technique for routinely 
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checking laboratory cultures for known common genetic change. However, both qPCR 
and FISH require pre-existing knowledge of genetic change in order to design primers 
or probes respectively. This is perhaps not on its own sufficient for clinical applications 
since we do not yet know the full range of genetic change in hPSC culture or its ability 
to cause harm, and so a more unbiased screening method may have to be employed 
as well. 
Another powerful genome wide screening method is SNP analysis whereby 
CNVs are revealed by the increase or decrease in nearby SNP markers detected by 
microarray platforms. A alternative is comparative genomic hybridisation arrays 
(aCGH), in which the comparison of sample to reference DNA is more integrated 
(Rassekh et al., 2008). By hybridizing differentially probed reference and test samples 
to a microarray the fluorescent ratios of each can be calculated. A ratio of 0 indicates 
normal or diploid condition whereas ratios of -1 or +1 indicate a loss or gain respectively 
for that region. This technique has already proved powerful in the field of oncology 
(Pinkel and Albertson, 2005). Neither SNP array or aCGH approaches require previous 
knowledge of the genetic change that may be present in a cell population. Furthermore, 
smaller CNVs of below 5Mb in length can be detected by SNP arrays with the resolution 
only limited by the distance between SNP markers. The usefulness of this technique 
has been demonstrated in the screening of 125 hESC lines revealing that greater than 
20% carried 20q11.21 CNVs that went largely undetected by karyotype analysis (Amps 
et al., 2011). However, although SNP based techniques are more precise in terms of 
the size of CNV they can detect, they do not provide improved sensitivity in detecting 
CNVs present in only a minority of cells. In mixing tests the ability of SNP microarray 
analysis to detect chromosome 8 trisomy became unreliable when it was present in 
less than 10% of the population (Cross et al., 2007). Similar testing of aCGH revealed 
that the smallest CNVs were only detected in 10-15% cultures (Valli et al., 2011). 
Another limitation to SNP based analysis is data interpretation. The sensitivity of the 
method for detecting small genetic changes means that numerous CNVs across all 
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chromosomes are identified during screening (Amps et al., 2011). However the majority 
of these will be stochastic in nature and will not produce a significant cellular 
phenotype. It is therefore a challenge to distinguish the relevant results from the 
background noise. 
Next generation sequencing (NGS) has revolutionised genome research and is 
increasingly used for the detection of structural variants. Many NGS approaches 
produce millions of short sequencing reads. By assuming that the distribution of these 
reads is random over the genome it is possible to infer duplications or deletions from 
areas that do not follow this trend (Tattini et al., 2015). However, as with other 
techniques, NGS often fail to detect low level variants of a mosaic population that are 
hidden by the normal signal. For example, in a study of tumor samples, a coverage as 
high as 10,000X was required to confirm the presence rare variants (Griffith et al., 
2015), Drawing parallels from this highlights the difficulty of sensitively detecting low 
level mosaicism in cultures of hPSCs. Also, sequencing of repetitive regions is still 
limited and sequencing or detection of the complete range of genetic variants may often 
require multiple strategies and sequencing approaches (Tattini et al., 2015).  
 
From these examples it is apparent that there are numerous methods for 
monitoring genetic change in hPSCs. However, none alone fulfil all of the requirements 
of a robust detection system. Karyotype analysis is still the best validated and most 
widely used technology in clinical applications (Whiting et al., 2015) and detects large 
aberrations, such as those of chromosomes 12 and 17, but we know that significant 
small CNVs can be missed. Probes for well characterised small CNVs, such as 
20q11.21, allow FISH analysis to extend the range of known genetic change that can 
be detected, but this requires prior knowledge of the CNVs to be assayed. In laboratory 
applications these techniques may be too labour intensive for routine assessment and 
so emerging techniques such as qPCR or interphase flow-FISH with a panel of primers 
or probes could allow one to screen for common genetic changes. In the case of either 
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clinical or laboratory applications it is important to recognise the limitations of detection 
methods and judgement is required to achieve satisfactory monitoring of genetic 
change in using hPSCs 
 
Minimising genetic change 
3HUWLQHQW WR WKH GLVFXVVLRQ RI DFTXLUHG JHQHWLF FKDQJH LQ K36&¶V LV ZKDW
measures can be taken to reduce the rate at which genetic variants appear, recognising 
that their appearance depends upon two unrelated mechanisms, namely mutation, 
followed by selection. Since much genetic change occurs through prolonged culture it 
is important to look closely at current methods of passaging and maintaining stem cells 
in culture. It is also important to discuss novel ways in which the mutation rate can be 
reduced and whether we can reduce the selection pressure for potentially harmful 
genetic change also. 
Soon after karyotype abnormalities were first linked to prolonged hPSC culture, 
investigations into the possible effect of different passaging techniques were 
conducted. For example one group showed that hESC lines could be maintained with 
a normal karyotype for prolonged periods using a manual passaging technique 
(Mitalipova et al., 2005). Furthermore, when these same lines were then switched to 
either enzymatic or non-enzymatic bulk passaging methods, characteristic genetic 
changes arose. Indeed a correlation between bulk passaging and karyotype 
abnormalities was documented in a large scale screen (Amps et al., 2011). Certainly 
the correlation between bulk passaging methods and acquired genetic change may 
may reflect the different stresses to which cells are exposed by different passaging 
techniques but it may also be partly due to the greater number of cells that are 
transferred in bulk methods. For example in a simulation study, the rate at which 
abnormal cells came to dominate the culture increased exponentially as the size of the 
overall cell population was increased (Olariu et al., 2010). This is likely a product of a 
greater number of cells undergoing individual mutational events, which increases the 
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likelihood of a cell acquiring an advantageous change. This effect could go some way 
to explaining the higher occurrence of acquired genetic change in hPSC cultures 
passaged by bulk methods, as the population size will be greater.  
The knowledge that population size affects the appearance of genetic variants 
in culture may provide an opportunity to modify culturing methods. For example, 
another finding from the simulation studies by Olariu et al. (2010), was that if the same 
number of cells was cultured in ten smaller sub-cultures the rate at which abnormal 
cells appeared was lower than in one single large population. The maintenance of 
hPSCs in small sub-cultures may therefore be an effective way to minimise the effect 
of genetic change in culture. Furthermore in the laboratory, if one sub-culture did 
acquire a significant level of genetic change then it could be easily discarded without 
abandoning the whole experiment. This may also be a useful consideration clinically 
since many potential regenerative medicine applications will require a significant 
number of cells. Therefore hPSCs could be expanded through lots of small sub-cultures 
before combining to produce the final treatment sample although this may not be cost 
effective or practical for the needs of clinical scale up. 
Another consideration regarding hPSC maintenance is how much selection 
pressure is created by culture methods. It has been documented that during the 
dissociation of hESC clumps during passaging a large amount of apoptosis occurs 
(Watanabe et al., 2007) and it was estimated that roughly 90% of cells are lost between 
each passage (Olariu et al., 2010). This therefore greatly increases the selection 
pressure for cells carrying genetic change that confers a growth advantage. Increasing 
the efficiency with which cells are passaged would reduce this selection pressure and 
therefore could reduce the occurrence of genetic change in culture. One study showed 
that a ROCK inhibitor could be used to reduce apoptosis during hESC dissociation 
which significantly increased colony formation after cell transfer and in recent years the 
use of ROCK inhibitor during hPSC passaging has become common place (Watanabe 
et al., 2007).  
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The predominant mechanism of mutation within hPSC culture is poorly 
understood, but studies have suggested novel ways by which to reduce the incidence 
of genetic change. For example oxidative stress is widely implicated in DNA damage 
and hiPSCs have been documented to have high ROS levels following reprogramming 
(Ji et al., 2014). Furthermore, supplementing hiPSC cultures with antioxidants such as 
vitamin C reduced ROS and the cells had a reduced number of de novo CNVs (Ji et 
al., 2014). The use of antioxidants would likely have a similar effect on the mutation 
rate in hESC culture as well. 
Another possible approach may be to use small molecule treatment in order to 
select against cells with different behaviour conferred by specific genetic variation. For 
example one group has demonstrated the increased sensitivity of hPSCs carrying 
trisomy of chromosome 12 to etoposide, cytarabine hydrochloride and gemcitabine 
hydrochloride (Ben-David et al., 2014), all DNA replication inhibitors already approved 
as anti-cancer therapies. Since many characterised hPSC genetic abnormalities confer 
a growth advantage a similar strategy could be employed in culture to select against 
these cells. 
 
Assessing the effects of genetic change 
 
 Despite the possible avenues for reducing genetic change it will be very difficult 
to culture hPSCs completely free of genetic alterations. Therefore it is very important 
that we are able to effectively assess genetic variants to distinguish between the 
problematic and the harmless.  
 The well documented chromosome 12 and 17 abnormalities can confer a 
growth advantage and, because of their large scale, they can cause aberrant 
expression of multiple genes in hPSCs (Draper et al., 2004). Gene expression data 
from TGCT show copy number increases along chromosome 17q (Skotheim et al., 
2002) and isochromosome 12 is used as a clinical marker for TGCT (Bosl et al., 1989). 
Furthermore investigators have reported a hESC carrying chromosome 12 gains with 
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neoplastic properties (Werbowetski-Ogilvie et al., 2009). Together these studies 
suggest that chromosome 12 and 17 abnormalities are unacceptable and therefore all 
clinical applications of hPSCs should require exclusion of these variants.  Most clinical 
trials include G banding karyotype screens so that, these large chromosomal 
abnormalities can be excluded with high confidence, providing a satisfactory number 
of metaphase spreads are analysed. However the question as to when and how often 
clinically destined samples should be analysed is still unresolved. 
 Large genetic variation detected at the karyotype level will usually not be 
acceptable for clinical use. However, a problem arises when considering smaller sub-
chromosomal CNVs. The 20q11.21 CNV confers a growth advantage to cells in a 
similar manner to that associated with chromosome 12 and 17 abnormalities. Therefore 
one would expect this to be a CNV that needs exclusion during clinical applications. 
This could be achieved using FISH analysis with a probe specific to the 20q11.21 
region. Furthermore, a spectrum of probes could be developed to screen cells for 
known CNVs.  However, genome wide SNP analysis reveals a vast array of CNVs of 
a similar size to the 20q11.21 (Amps et al., 2011). The problem therefore is that 
currently we have more data than knowledge. Of the array of CNVs detected using 
genome wide techniques which, if any, are potentially harmful, either because the 
variant promotes transformation and the development of cancer, or because it affects 
the function of the derivative cells to be used for therapy?  In either case the answer 
will be dependent upon the types of derivative cells produced. For example, the 
potential for converting non-dividing derivative cells such as cardiomyocytes to 
malignant derivatives is likely to be substantially less than for differentiated cells that 
still retain proliferative potential, such as hepatocytes. 
 Clues to the possible consequences for malignancy of genetically variant hPSC 
derivatives requiremay be obtained from the various cancer genome databases that 
are now being developed, for example from the International Cancer Genome 
Consortium (http://icgc.org/). However, direct assessment of malignant potential will 
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requirein vivo studies. For example, in one study investigators took a hESC line 
harbouring the 20q11.21 CNV with high proliferative capacity and growth factor 
independence (Werbowetski-Ogilvie et al., 2009), and transplanted neural derivatives 
into mice where they formed tumours (Werbowetski-Ogilvie et al., 2012). Similar 
studies where other recurrent CNVs are tested in vivo could help in the assessment of 
hPSC genetic variation. 
 Critical effects of genetic variants on cell function will necessarily have to be 
tailored to the specific cell types being produced, and could involve either in vivo or in 
vitro studies as appropriate. For example a vital function of cardiomyocytes is their 
characteristic calcium handling, which has been used to compare hiPSC derived 
cardiomyocytes to somatic cells (Hwang et al., 2015). 6LPLODU VWXGLHV ZLWK K36&¶V
carrying a particular CNV could reveal whether the genetic variation disrupts the 
function of the specialized derivative. This would be extremely important for validating 
K36&¶VDVGHYHORSPHQWDODQGGLVHDVHmodels.. 
 
Conclusion 
  Acquired genomic change is a concern for both its potential to confound the 
results of basic research and to jeopardise the safety of clinical applications. Despite 
this, trials using pluripotent stem cell products are in progress. The first such trial was 
launched by Geron in 2010 which aimed to use oligodendrocyte hESC derivatives to 
treat spinal cord injury. It was discontinued in 2011 due to financial constraints, but a 
follow up of the patients occurred at three years (Asterias, 2014). Cardiac progenitors 
from hESCs have also been used in a trial on heart failure (Menasché et al., 2015). A 
number of hESC based trials for macular degeneration are also underway including 
studies launched by Pfizer (Pfizer and London, 2012) and Ocata therapeutics 
(Schwartz et al., 2015). Thus far, no adverse effects relating to genomic change have 
been reported in any of these trials.  However, it is important to remain vigilant. 
19 
 Monitoring genetic change has different requirements for specific applications. 
In basic research efficient, affordable methods are likely to be employed so that they 
can be applied routinely. Promising techniques, utilizing qPCR and flow cytometry, are 
therefore likely to be important developments. Monitoring genetic change for clinical 
applications is likewise changing. For example, in the earliest trial aimed at treating 
macular degeneration, whilst a normal karyotype was confirmed, further high-resolution 
techniques were not used (Schwartz et al., 2012). However, in a more recent trial, FISH 
analysis using probes for loci on chromosomes 12, 17 and 20 was employed to screen 
for well characterized changes associated with hPSC culture (Menasché et al., 2015). 
As our knowledge of genomic variation grows, additional probes could be added to this 
list to exclude other genetic changes. An argument can be made that the technology 
to indiscriminately screen the whole genome for small CNVs is available in the form of 
NGS, aCGH and SNP analysis and so should be used. However the difficulty of 
defining what is a significant genetic change and what is part of normal variation 
presents a difficulty. 
 As discussed, one method to assess the significance of genetic variation is 
through in vivo studies. This already forms a major step in bringing any stem cell based 
treatment to the clinic. The first macular degeneration trial was preceded by pre-clinical 
studies in 45 rats which confirmed the safety of the hPSC derived treatment in vivo 
12(Li et al., 2012). Since macular degeneration is a disease of the eyes the treatment 
area is relatively small. This meant the same number of cells (5x104) could be tested 
in the model as was used in the human trial (Schwartz et al., 2012). A problem that 
may arise as hPSC based treatments for larger organs are developed is that the 
number of cells required will increase. It may, therefore, not be feasible to test the same 
number of cells in some model organisms due to the relative size of the organ. This is 
an important consideration because much acquired genetic change occurs during 
prolonged passage. Therefore, if pre-clinical trials are performed using a smaller 
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number of cells then the possibility arises that in the human trial the extended culture 
time required to produce the required cell number will introduce more genetic change. 
 As hPSCs continue to be used it is likely that protocols will be adjusted to 
minimize genetic change. For example, a recently launched trial using hiPSC derived 
retinal pigment epithelium to treat macular degeneration (David, 2014) was put on hold 
due to the detection of a cancer related mutation in the hiPSC sample (Andy, 2015). 
This change was not detected in the original skin cells, so could either have been 
present at undectable levels or were caused by the reprogramming procedure (Andy, 
2015). The risk associated with this reprogramming technique is likely to lead to an 
increased movement towards non-integrative reprogramming techniques such as 
episomal vectors (Yu et al., 2009). Splitting hPSC cultures into smaller sub-cultures, 
reducing selection pressure, and using antioxidants may also help to reduce the 
occurrence of acquired genetic change in culture. 
Encouragement can be taken from the lack of adverse effects in human trials 
using hPSCs to this point. However, it is imperative that this remains the case with 
future trials for both the safety of patients and to prevent stalling of hPSC applications. 
This aim will be aided by continual consideration of the monitoring, minimizing and 
assessment of genomic variation in the context of both basic research and clinical 
applications.   
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Table 1.  The sensitivity of detecting karyotypically variant cells in mosaic cultures by G-
Banding karyology 
 
Number of Metaphases 
Scored 
Percent Variant Cells Detected 
with 95% Confidence 
  
20 28% 
30 18% 
50 13% 
60 10% 
100 6% 
500 < 1% 
  
 
The table shows, based on statistical sampling theory, the minimum proportion of variant 
cells that would be detected in mosaic cultures for different numbers of metaphases scored 
(Baker et al 2016).  By screening test cultures with different proportions of variant hESC, the 
actual sensitivity of G-banding karyology carried out using standard procedures closely 
matched the expected sensitivity predicted by statistical sampling theory. 
 
 
